Angiotensin I ELISA Kit
Cat# OKEH02621
Size : 96Wells
Brand : Aviva Systems Biology
Predicted Species Reactivity | All Species | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Application | Enzyme-linked Immunosorbent assay-Competitive | ||||||||||||||||||||||
ELISA Kit Detection Method | Colorimetric, OD450 nm | ||||||||||||||||||||||
ELISA Kit Duration | ~ 3 Hours | ||||||||||||||||||||||
ELISA Kit Principle | Aviva Systems Biology Angiotensin I ELISA Kit (OKEH02621) is based on a competitive enzyme immunoassay technique. The microtiter well-plate in this kit has been pre-coated with an anti-Angiotensin I antibody. Sample or standards are added to the wells along with a fixed quantity of biotinylated Angiotensin I and incubated. The Angiotensin I found in the sample or standards competes with the biotinylated Angiotensin I for limited binding sites on the immobilized anti-Angiotensin I antibody. Excess unbound biotinylated Angiotensin I and sample or standard Angiotensin I is washed from the plate. Avidin-HRP conjugate is added, incubated and washed. An enzymatic reaction is then produced through the addition of TMB substrate which is catalyzed by the immobilized HRP to generate a blue color product that changes yellow after adding acidic stop solution. The density of yellow coloration is measured by reading the absorbance at 450 nm which is quantitatively proportional to the amount of biotinylated Angiotensin I captured in the well and inversely proportional to the amount of Angiotensin I which was contained in the sample or standard. | ||||||||||||||||||||||
ELISA Kit Range | 78-5000pg/mL | ||||||||||||||||||||||
ELISA Kit Recovery | Mean recovery when spiking into Serum and Plasma = 103% | ||||||||||||||||||||||
ELISA Kit Reproducibility | Mean Intra-assay CV%: < 5.3% (n = 20) Mean Inter-assay CV%: < 9.6% (n = 20) | ||||||||||||||||||||||
ELISA Kit Component |
| ||||||||||||||||||||||
Additional Information | Target Abbr: Ang-I Target Name: Angiotensin I | ||||||||||||||||||||||
:: | Pubchem: 3081372 | ||||||||||||||||||||||
:: | Chemical formula: C62H89N17O14 | ||||||||||||||||||||||
Reconstitution and Storage | Store as indicated in product manual. | ||||||||||||||||||||||
Sample Type | Serum, plasma, tissue homogenates, cell culture supernatants and other biological fluids | ||||||||||||||||||||||
Sensitivity | 22 pg/mL | ||||||||||||||||||||||
Specificity | Natural and recombinant General Angiotensin I | ||||||||||||||||||||||
Assay Info | Assay Methodology: Quantitative Competitive ELISA |
Alias Symbols | Ang-I, Angiotensin I, Ang-I |
---|---|
Protein Name | Angiotensin I |
Description of Target | Angiotensins are small peptides derived from angiotensinogen. Several of the known Angiotensins are established endocrine effectors in the regulation of blood pressure, but they are also known to have other functions locally, in several organs and tissues (paracrine) and at the cellular level (autocrine / intracrine). Angiotensin I has no known effector function but it is an immediate precursor of Angiotensin II. Angiotensin II binds AT1 receptors, which promote vasoconstriction, sodium retention, release of aldosterone, release of Argâ€vasopressin, cell proliferation, inflammation, fibrosis, anxiety, and cardiac hypertrophy. Angiotensin A and Angiotensin III, also bind AT1 receptors. Angiotensin ( 7) binds a different receptor called MASâ€1 which has opposite effects (vasodilation, natriuresis, antiproliferation, NO release, PGE release, and apoptosis). Angiotensin IV binds yet another receptor called AT4 (IRAP), which promotes increase of blood flow, angiogenesis, and natriuresis, and which has also been implicated in memory formation and in the pathogenesis of Alzheimer’s disease. The peptide LVVâ€hemorphinâ€7, which is not an angiotensin, also binds the AT4 receptor. There are other angiotensin peptides that Discover more at www.abcam.com 3 INTRODUCTION have been identified, including Ang ( 9), Ang ( 12), Ang V( 7), as well as several other shorter peptides that have undetermined functions. Angiotensins can be present in very low concentrations in some biological samples. In such cases, dilution of samples to avoid “nonâ€specific†interference by any present factors is not productive because the angiotensin analyte is also diluted to levels far below the minimum detection concentration. Thus, investigators have used several procedures for extracting Angiotensins from biological samples prior to using them for immunoassays. Angiotensins share common sequences, and in some cases they cannot be discriminated by immunoassays. Prior extraction and separation by HPLC may, thus, be required. |